/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Lexicon Pharmaceuticals, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.35 0.0448(4.48%) LXRX at 04 Dec 2025 04:38 PM Biotechnology
Lowest Today 1.34
Highest Today 1.41
Today’s Open 1.34
Prev. Close 1.34
52 Week High 1.66
52 Week Low 0.28
Day’s Range: Low 1.34 High 1.41
52-Week Range: Low 0.28 High 1.66
1 day return -
1 Week return -1.74
1 month return +4.85
3 month return +30.69
6 month return +112.39
1 year return +105.74
3 year return -35.25
5 year return -11.07
10 year return -

Institutional Holdings

Artal Group S A 37.47

Siren, L.L.C. 10.71

FMR Inc 10.49

Fidelity Growth Compy Commingled Pl S 4.98

Fidelity Growth Company Fund 3.41

Vanguard Group Inc 2.44

Vanguard Total Stock Mkt Idx Inv 1.39

Schonfeld Strategic Advisors LLC 1.26

Fidelity Growth Company K6 1.09

BlackRock Inc 0.92

Fidelity Series Growth Company 0.89

Sessa Capital IM LP 0.83

GSA Capital Partners LLP 0.78

Atlantic Trust Group, LLC 0.67

Geode Capital Management, LLC 0.65

Vanguard Institutional Extnd Mkt Idx Tr 0.55

Millennium Management LLC 0.45

Fidelity Select Biotechnology 0.42

AQR Capital Management LLC 0.39

Fidelity Extended Market Index 0.28

Charles Schwab Investment Management Inc 0.24

Schwab US Small-Cap ETF™ 0.24

State Street Corp 0.23

Jane Street Group LLC 0.22

Hennion & Walsh Asset Management Inc 0.22

Royal Bank of Canada 0.21

Susquehanna International Group, LLP 0.21

Vanguard Health Care ETF 0.15

Monaco Asset Management 0.15

HRT FINANCIAL LLC 0.13

Extended Equity Market Fund K 0.11

Invesco RAFI US 1500 Small-Mid ETF 0.09

Fidelity Total Market Index 0.09

Fidelity Nasdaq Composite Index 0.07

Fidelity Series Total Market Index 0.07

Spartan Extended Market Index Pool F 0.06

Northern Trust Extended Eq Market Idx 0.06

NT Ext Equity Mkt Idx Fd - L 0.06

iShares Nasdaq US Biotech ETF USD Acc 0.06

NT Ext Equity Mkt Idx Fd - NL 0.05

Market Status

Strong Buy: 1

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 486.95 M

PB Ratio 4.1433

PE Ratio 0.0

Enterprise Value 440.06 M

Total Assets 298.42 M

Volume 1531642

Company Financials

Annual Revenue FY23:530000 0.5M, FY22:139000 0.1M, FY21:298000 0.3M, FY20:23995000 24.0M, FY19:322073000 322.1M

Annual Profit FY23:515000 0.5M, FY22:139000 0.1M, FY21:298000 0.3M, FY20:22066000 22.1M, FY19:318842000 318.8M

Annual Net worth FY23:-157857000 -157.9M, FY22:-103128000 -103.1M, FY21:-88268000 -88.3M, FY20:-70184000 -70.2M, FY19:130133000 130.1M

Quarterly Revenue Q3/2025:14182000 14.2M, Q2/2025:28866000 28.9M, Q1/2025:1262000 1.3M, Q3/2024:1750000 1.8M, Q2/2024:1647000 1.6M

Quarterly Profit Q3/2025:14172000 14.2M, Q2/2025:28657000 28.7M, Q1/2025:1232000 1.2M, Q3/2024:1679000 1.7M, Q2/2024:1481000 1.5M

Quarterly Net worth Q3/2025:-12769000 -12.8M, Q2/2025:3252000 3.3M, Q1/2025:-25295000 -25.3M, Q3/2024:-64811000 -64.8M, Q2/2024:-53429000 -53.4M

Fund house & investment objective

Company Information Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Organisation Biotechnology

Employees 103

Industry Biotechnology

CEO Dr. Michael S. Exton Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow